|
|
|
|
||
3.40 resistance level3.40 is where we were when there was hope the subset of high folate forward 1 data was being reviewed by the FDA in hopes Mirve might be approved for this subset. It looks like we may breakthrough that prior to ESMO meeting. Good forward 2 data and a possibly the new forward 3 study design and more precise date to start enrolling can push higher. Good ash imgn 632 data may get us to 5. Then it’s either going to be stuck there for quite awhile or partner news such as Jazz opt in and mirve OUS that drives it higher. And who knows, possible buyout at that point is possible too. |
return to message board, top of board |